Date:11/19/2007

Phase II clinical results are expected to be released in the 1st half of 2008. The GI Company also has pre-clinical development programs in enteritis/proctitis, inflammatory bowel disease, erosive gastroesophageal reflux disease, peptic ulcer disease and gastrointestinal motility disorders, as well as clinical programs in erosive gastritis (NSAID induced), ulcerative colitis and corneal wound healing. For more information, visit http://www.thegicompany.com.

About LaVoie Group

LaVoie Group provides senior level strategic counsel and tactical implementation of public, investor and corporate communications programs designed to properly position, create visibility and drive value for each client. Our clients range from private start-ups to industry leaders in life sciences. For more information, visit http://www.lavoiegroup.com.

'/>"/>

SOURCE LaVoie Group Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. Broad-based group of physicians calls for improvement in stroke treatment
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. CIGNA Group Insurance Shows Consumers Theres More to Life Through a New Consumer Education Toolkit
4. HIDA Calls for Scrutiny of Group Purchasing Organization Distributor Fee Structure
5. New Research Uncovers how to Build and Maintain an Effective Competitive Intelligence Group
6. AMERIGROUP to Acquire Memphis Health Plan
7. Securians Minnesota Life Continues to Climb Group Life Rankings
8. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
9. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
10. Group B Strep: A Threat to Newborns That Doesnt Have to Be
11. Cynosure to Present at the Maxim Group Growth Conference